Judith Jo
- Oncology top 5%
- HER2/EGFR in Cancer Research 7
- Cancer Treatment and Pharmacology 3
-
- Monoclonal and Polyclonal Antibodies Research 4
- Reproductive Medicine top 10%
- Ovarian cancer diagnosis and treatment 3
-
- Prostate Cancer Treatment and Research 3
-
- Glycosylation and Glycoproteins Research 3
- Molecular Biology Techniques and Applications 2
- TGF-β signaling in diseases 2
- Co-authors
- Xavier FilellaAntonio M. BallestaRafael MolinaA M BallestaJaume PahisaB. FarrúsGabriel ZanónMontserrat Muñoz-Mateu
- Journals
- Tumor Biology (5 papers)The International Journal of Biological Markers (4 papers)Clinical Chemistry (2 papers)
- Partner nations
- SpainUnited StatesFrance
In The Last Decade
Judith Jo
22 papers receiving 809 citations
Peers
Comparison fields: 5 of 65
- Oncology 508
- Radiology, Nuclear Medicine and Imaging 250
- Cancer Research 149
- Reproductive Medicine 82
- Pulmonary and Respiratory Medicine 159
Countries citing papers authored by Judith Jo
This map shows the geographic impact of Judith Jo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Judith Jo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Judith Jo more than expected).
Fields of papers citing papers by Judith Jo
This network shows the impact of papers produced by Judith Jo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Judith Jo. The network helps show where Judith Jo may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Judith Jo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 3 | |
| 2 | 2023 | 0 | |
| 3 | 2000 | 14 | |
| 4 | C-erbB-2, CEA and CA 15.3 serum levels in the early diagnosis of recurrence of breast cancer patients. | 1999 | 74 |
| 5 | 1999 | 19 | |
| 6 | 1998 | 106 | |
| 7 | 1998 | 28 | |
| 8 | 1997 | 57 | |
| 9 | C-erbB-2 oncoprotein in the sera and tissue of patients with breast cancer. Utility in prognosis. | 1996 | 42 |
| 10 | 1996 | 28 | |
| 11 | 1996 | 60 | |
| 12 | 1996 | 14 | |
| 13 | 1995 | 100 | |
| 14 | 1994 | 60 | |
| 15 | 1994 | 51 | |
| 16 | 1993 | 3 | |
| 17 | 1992 | 32 | |
| 18 | 1991 | 78 | |
| 19 | 1990 | 10 | |
| 20 | 1990 | 45 |
About Judith Jo
Judith Jo is a scholar working on Oncology, Reproductive Medicine and Orthopedics and Sports Medicine, having authored 23 papers that have together received 852 indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (7 papers), Monoclonal and Polyclonal Antibodies Research (4 papers), Glycosylation and Glycoproteins Research (3 papers), Cancer Treatment and Pharmacology (3 papers), Ovarian cancer diagnosis and treatment (3 papers), Prostate Cancer Treatment and Research (3 papers), Molecular Biology Techniques and Applications (2 papers) and TGF-β signaling in diseases (2 papers). The work is most often cited by research in Oncology (508 citations), Radiology, Nuclear Medicine and Imaging (250 citations) and Cancer Research (149 citations). Judith Jo has collaborated with scholars based in Spain, United States and France. Frequent co-authors include Xavier Filella, Antonio M. Ballesta, Rafael Molina, A M Ballesta, Jaume Pahisa, B. Farrús, Gabriel Zanón, Montserrat Muñoz-Mateu, Rafael Molina and Carles Agustı́. Their work appears in journals such as Tumor Biology, The International Journal of Biological Markers, Clinical Chemistry, The Prostate and Breast Cancer Research and Treatment.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.